Literature DB >> 10464142

Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome.

H Tsujii1, J König, D Rost, B Stöckel, U Leuschner, D Keppler.   

Abstract

BACKGROUND & AIMS: The Dubin-Johnson syndrome is characterized by conjugated hyperbilirubinemia and by impaired secretion of anionic conjugates from hepatocytes into bile. Absence of the multidrug-resistance protein 2 (MRP2; symbol ABCC2), an adenosine triphosphate-dependent conjugate export pump, from the hepatocyte canalicular membrane is the molecular basis of this syndrome. The aim of this study was the elucidation of all exon-intron boundaries of the MRP2 gene as a prerequisite for the analysis of mutations in patients with Dubin-Johnson syndrome.
METHODS: Exon-intron boundaries of MRP2 were determined, and the amplified exons were screened for mutations. Immunofluorescence microscopy served to localize the MRP2 protein in human liver.
RESULTS: The human MRP2 gene is approximately 45 kilobases long; it contains 32 exons and a high proportion of class 0 introns. In 2 patients with Dubin-Johnson syndrome, we detected a nonsense mutation at codon 1066 and a 6-nucleotide deletion mutation affecting codons 1392-1394. The MRP2 protein was absent from the canalicular membrane of both patients.
CONCLUSIONS: The mutations detected so far show that various mutations in the MRP2 gene can lead to the Dubin-Johnson syndrome. The exon-intron boundaries established in this article will facilitate the analysis of additional mutations in the MRP2 gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464142     DOI: 10.1016/s0016-5085(99)70459-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

Review 1.  The molecular genetics of familial intrahepatic cholestasis.

Authors:  P L Jansen; M Müller
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

2.  Expression of liver plasma membrane transporters in gallstone-susceptible and gallstone-resistant mice.

Authors:  Oliver Müller; Carmen Schalla; Jürgen Scheibner; Eduard F Stange; Michael Fuchs
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

Review 3.  Interplay of drug metabolizing enzymes with cellular transporters.

Authors:  Michaela Böhmdorfer; Alexandra Maier-Salamon; Juliane Riha; Stefan Brenner; Martina Höferl; Walter Jäger
Journal:  Wien Med Wochenschr       Date:  2014-09-10

4.  Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing.

Authors:  Iñigo Narvaiza; Oscar Aparicio; María Vera; Nerea Razquin; Sergia Bortolanza; Jesús Prieto; Puri Fortes
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

5.  Relationship between loperamide-induced sedative effect and digoxin pharmacokinetics in healthy Japanese subjects.

Authors:  Michiya Kobayashi; Hiroshi Saitoh; Michiko Yamaguchi; Takeshi Saito; Hiroyoshi Fujita; Manabu Suno; Kazuo Matsubara; Bruce J Aungst
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

Review 6.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2).

Authors:  Vandana Megaraj; Tianyong Zhao; Christian M Paumi; Phillip M Gerk; Richard B Kim; Mary Vore
Journal:  Pharmacogenet Genomics       Date:  2011-08       Impact factor: 2.089

8.  Identification of a novel 2026G-->C mutation of the MRP2 gene in a Japanese patient with Dubin-Johnson syndrome.

Authors:  Shinya Wakusawa; Ikuo Machida; Satoshi Suzuki; Hisao Hayashi; Motoyoshi Yano; Kentaro Yoshioka
Journal:  J Hum Genet       Date:  2003-07-22       Impact factor: 3.172

9.  Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.

Authors:  Giulia Ghibellini; Elaine M Leslie; Gary M Pollack; Kim L R Brouwer
Journal:  Pharm Res       Date:  2008-05-30       Impact factor: 4.200

10.  Hepatobiliary transport in health and disease.

Authors:  Jeannie Chan; John L Vandeberg
Journal:  Clin Lipidol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.